Resumen de acción ALDX Aldeyra Therapeutics, Inc, empresa de biotecnología, desarrolla y comercializa medicamentos para enfermedades inmunomediadas. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Aldeyra Therapeutics, Inc. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Aldeyra Therapeutics Precios históricos de las acciones Precio actual de la acción US$5.02 Máximo en las últimas 52 semanas US$6.55 Mínimo de 52 semanas US$2.71 Beta 1.37 Cambio en 1 mes 4.58% Variación en 3 meses -8.73% Cambio de 1 año 39.06% Variación en 3 años 23.65% Variación en 5 años -15.77% Variación desde la OPV -30.28%
Noticias y actualizaciones recientes
New minor risk - Profitability Nov 14
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease Oct 03
Chief Development Officer recently sold US$76k worth of stock Aug 15
Chief Development Officer notifies of intention to sell stock Aug 14
Price target increased by 8.1% to US$10.00 Aug 12
New minor risk - Share price stability Aug 08 Ver más actualizaciones
New minor risk - Profitability Nov 14
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease Oct 03
Chief Development Officer recently sold US$76k worth of stock Aug 15
Chief Development Officer notifies of intention to sell stock Aug 14
Price target increased by 8.1% to US$10.00 Aug 12
New minor risk - Share price stability Aug 08
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap Aug 08
Consensus EPS estimates fall by 209% Aug 08
New minor risk - Profitability Aug 05
No longer forecast to breakeven Aug 05 Aldeyra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Aug 02
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt? Jun 21
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable Jun 20
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease Jun 15
Consensus EPS estimates upgraded to US$0.18 loss May 23
Forecast to breakeven in 2026 May 22
Consensus EPS estimates fall by 163% May 12
Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease May 09
No longer forecast to breakeven May 06
New minor risk - Profitability May 05
Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024 Apr 23
New minor risk - Profitability Apr 03
No longer forecast to breakeven Apr 03
Forecast to breakeven in 2024 Mar 29
New minor risk - Profitability Mar 28
Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease Mar 28
CEO, President & Director recently sold US$581k worth of stock Mar 14
CEO, President & Director notifies of intention to sell stock Mar 13
Forecast to breakeven in 2024 Mar 11
New minor risk - Profitability Mar 10
Forecast to breakeven in 2024 Mar 08
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load? Feb 16
Consensus revenue estimates increase by 55% Jan 30
Consensus revenue estimates increase by 57% Jan 05
Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis Dec 19
Consensus revenue estimates increase by 600% Dec 06
New minor risk - Profitability Nov 29
Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease Nov 29
Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease Nov 28
Consensus revenue estimates decrease by 82%, EPS upgraded Nov 10
Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt? Nov 06
New minor risk - Market cap size Oct 19
New minor risk - Profitability Oct 18
Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease Oct 17
Consensus revenue estimates decrease by 61%, EPS upgraded Oct 17
Price target decreased by 13% to US$17.86 Oct 16
CEO, President & Director exercised options and sold US$492k worth of stock Sep 13
Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc Sep 01
Consensus revenue estimates increase by 36% Aug 22
Consensus revenue estimates decrease by 73%, EPS upgraded Aug 10
Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, Inc Aug 02
Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough Jun 28
Consensus revenue estimates increase by 15% Jun 22
Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis Jun 16
Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023 May 25
Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry? Mar 26
Consensus revenue estimates decrease by 41%, EPS upgraded Mar 16
Price target increased by 8.4% to US$21.83 Mar 12
Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease Trials Feb 18
Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease Feb 08
Forecast to breakeven in 2025 Feb 02
Insufficient new directors Feb 01
Aldeyra Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma Dec 22
Aldeyra Therapeutics, Inc. Announces Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial Dec 14
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA Dec 03
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease Nov 30
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt? Nov 19
Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Part 1 of Phase 3 Guard Trial of Adx-2191 in Proliferative Vitreoretinopathy Oct 07
Aldeyra Therapeutics, Inc. Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA Sep 15
Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment Sep 14
Insider recently bought US$1.1m worth of stock Aug 04
Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization Aug 04
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way? Aug 03
Aldeyra Therapeutics, Inc. Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial Jul 13
Aldeyra says trial for dry eye disease candidate reached key goals Jul 12
CEO, President & Director recently bought US$60k worth of stock Jun 28
Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Phase 3 Tranquility-2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease Jun 09
Aldeyra Therapeutics, Inc. Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease May 26
Aldeyra Therapeutics, Inc. Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease May 25
Aldeyra Therapeutics Announces That Post-Hoc Analysis Using Computer Automated Grading of Phase 3 Tranquility Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap over Vehicle for Primary Endpoint of Ocular Redness May 19
Price target decreased to US$20.89 Apr 27
Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 07, 2022 Apr 26
Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry? Apr 19
Aldeyra Therapeutics, Inc. Announces Completion of Enrollment in Phase 3 Tranquility-2 Trial in Patients with Dry Eye Disease Apr 06
Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day Mar 30
No longer forecast to breakeven Mar 19 Aldeyra Therapeutics, Inc. Initiates Phase 2 Clinical Trial of ADX-2191 for the Treatment of Retinitis Pigmentosa Mar 10
Forecast to breakeven in 2024 Feb 24
Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts Feb 17
Aldeyra Therapeutics, Inc. Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model Feb 02
Forecast to breakeven in 2024 Jan 25
Aldeyra Therapeutics, Inc Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra Jan 12
Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy Jan 05
Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap Dec 23 Rentabilidad de los accionistas ALDX US Biotechs Mercado US 7D 3.3% 2.6% 2.8% 1Y 39.1% -3.3% 24.6%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: ALDX superó a la industria US Biotechs, que obtuvo un rendimiento del -3.3% el año pasado.
Rentabilidad vs. Mercado: ALDX superó al mercado US, que obtuvo un rendimiento del 24.6% el año pasado.
Volatilidad de los precios Is ALDX's price volatile compared to industry and market? ALDX volatility ALDX Average Weekly Movement 8.7% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.4% 10% least volatile stocks in US Market 3.1%
Precio estable de las acciones: ALDX no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ALDX (9%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Aldeyra Therapeutics, Inc. es una empresa biotecnológica que desarrolla y comercializa medicamentos para enfermedades inmunomediadas. Su principal producto candidato es el reproxalap, un modulador de las especies aldehídicas reactivas (RASP), que se encuentra en fase III de ensayo clínico para el tratamiento de la sequedad ocular. La empresa también desarrolla ADX-629, un modulador de la RASP administrado por vía oral para el tratamiento de la COVID-19, el asma atópica, la psoriasis y la intoxicación etílica; y ADX-2191, un inhibidor de la dihidrofolato reductasa para el tratamiento de la retinosis pigmentaria, así como de enfermedades raras de la retina caracterizadas por la inflamación y la pérdida de visión.
Mostrar más Resumen de fundamentos de Aldeyra Therapeutics, Inc. ¿Cómo se comparan los beneficios e ingresos de Aldeyra Therapeutics con su capitalización de mercado? Estadísticas fundamentales de ALDX Capitalización bursátil US$283.16m Beneficios(TTM ) -US$44.80m Ingresos (TTM ) n/a
0.0x Ratio precio-ventas (PS)
-6.7x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de ALDX Ingresos US$0 Coste de los ingresos US$0 Beneficio bruto US$0 Otros gastos US$44.80m Beneficios -US$44.80m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.75 Margen bruto 0.00% Margen de beneficio neto 0.00% Ratio deuda/patrimonio 18.0%
¿Cómo se ha desempeñado ALDX a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/26 19:47 Precio de las acciones al final del día 2024/12/26 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Aldeyra Therapeutics, Inc. está cubierta por 22 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Raghuram Selvaraju Aegis Capital Corporation Keay Nakae Ascendiant Capital Markets LLC Esther Lannie Hong Berenberg
Mostrar 19 más analistas 
